Scientists discover how cancer hides from immune system—and how to expose it

Researchers have identified the molecular trick that lets pancreatic cancer cells slip past the immune system undetected. An international team found that a protein called MYC, long known to drive tumor growth, does something unexpected under stress: it reorganizes inside the cell to actively suppress the immune system's warning signals. When they blocked this hidden function in animal studies, tumors collapsed by 94 percent.

The discovery, published in Cell, comes from Leonie Uhl, Amel Aziba, and Sinah Löbbert at the University of Würzburg, MIT, and colleagues led by Martin Eilers. It reveals a separation in how cancer works that could change how we treat it.

The Invisibility Mechanism

MYC is famous in cancer biology for one job: pushing cells to divide. Tumors with high MYC activity grow aggressively. But they also tend to survive despite the immune system's patrol. The puzzle was why.

The research shows MYC does double duty. Under the stress of rapid tumor growth, it shifts behavior. Instead of sticking to DNA to activate growth genes, it binds to newly formed RNA molecules. This triggers a cascade: multiple MYC proteins cluster together, forming dense structures that act like molecular magnets. These clusters pull in the exosome complex—a cellular cleanup crew—and concentrate it in one spot.

Once gathered, the exosome complex removes RNA-DNA hybrids, which are faulty byproducts of gene activity that normally scream "something's wrong here" to the immune system. By clearing these warning signals before they reach immune cells, MYC effectively turns off the alarm. The tumor becomes invisible.

"While pancreatic tumors with normal MYC grew 24-fold in 28 days, tumors with a defective MYC protein shrank by 94 percent—but only if the animals' immune systems were intact," explains Eilers. Once the immune system could see the cancer, it dismantled it.

Why This Matters for Treatment

Previous attempts to fight cancer by blocking MYC entirely have failed because the protein is essential for normal cells too. Shut it down completely and you damage healthy tissue.

This discovery opens a narrower path. The growth-promoting function of MYC and its immune-evasion function operate through separate mechanisms. Future drugs could theoretically target only the RNA-binding ability, leaving MYC's growth role intact while lifting the tumor's cloak. The immune system could then recognize and attack cancer cells again.

Clinical applications remain years away. Researchers must still understand how these warning signals escape the cell nucleus and how MYC's RNA-binding activity affects the tumor's surroundings. But the finding represents a shift from brute-force cancer treatment toward something more precise: not killing the growth driver, but exposing the hiding place.